AbbVie Inc. (NYSE:ABBV) | Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie

[Business Wire] – Seattle Genetics, Inc. today announced that it has further expanded its antibody-drug conjugate collaboration with AbbVie . Under the expanded deal, AbbVie will pay an upfront fee of $25 million . . . → Read More: AbbVie Inc. (NYSE:ABBV) | Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie